<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554927</url>
  </required_header>
  <id_info>
    <org_study_id>WEBAPPAC</org_study_id>
    <nct_id>NCT04554927</nct_id>
  </id_info>
  <brief_title>Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer</brief_title>
  <acronym>WEBAPPAC</acronym>
  <official_title>Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the implementation of a Web-application in patients&#xD;
      initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence&#xD;
      and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">September 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observance of hormontherapy</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life with self questionnaires</measure>
    <time_frame>18 months</time_frame>
    <description>Quality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life with self questionnaires</measure>
    <time_frame>18 months</time_frame>
    <description>uality of life scores according (EORTC QLQ-BR23 self-questionnaires ; minimum not at all to maximum Lot; 23 questions)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Web-application</condition>
  <condition>Breast Cancer</condition>
  <condition>Hormono Therapy</condition>
  <arm_group>
    <arm_group_label>WEB-application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard accompaniment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>WEB-Application</intervention_name>
    <description>The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).</description>
    <arm_group_label>WEB-application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard accompaniment</intervention_name>
    <description>Personalized schedule of medical follow-up given to the patient</description>
    <arm_group_label>Standard accompaniment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient &gt; 18 years old&#xD;
&#xD;
          -  Breast cancer patient candidate for adjuvant hormone therapy&#xD;
&#xD;
          -  Mastery of the French language&#xD;
&#xD;
          -  Patient with a cell phone and an Internet connection&#xD;
&#xD;
          -  Patient able to use a computer, smartphone, or tablet.&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Signing of informed consent prior to any specific study-related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has previously received hormone therapy for cancer.&#xD;
&#xD;
          -  Patient not trained in the use of the application&#xD;
&#xD;
          -  Any associated medical or psychiatric condition that might compromise the patient's&#xD;
             ability to participate in the study&#xD;
&#xD;
          -  Patients with locoregional or metastatic recurrence&#xD;
&#xD;
          -  Other history of cancer.&#xD;
&#xD;
          -  Patient deprived of liberty, under guardianship or curatorship&#xD;
&#xD;
          -  Simultaneous participation in a therapeutic clinical trial or other clinical study&#xD;
             involving a connected tool&#xD;
&#xD;
          -  Patient unable to undergo trial follow-up for geographical, social or&#xD;
             psychopathological reasons&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre François baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GERNIER, Study nurse</last_name>
      <phone>+ 33 2 31 45 50 50</phone>
      <email>f.gernier@baclesse.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel GRELLARD, project manager</last_name>
      <phone>+ 33 2 31 45 50 50</phone>
      <email>jm.grellard@baclesse.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François GERNIER, Study nurse</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaelle ANNE, Study nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte CEINTRE, Study nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rose-Marie CHARLES, Study nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey FAVEYRIAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emile GEORGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djelila ALLOUACHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien GEFFRELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine SEGURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina GUNZER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioana HRAB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison JOHNSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline MOREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

